Document is current

Any future updates will be listed below

Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs

Crossref DOI link: https://doi.org/10.1186/s12876-026-04791-9

Published Online: 2026-04-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark